Umeaux D, CraxsirtuininhibitorA, Chaneac M, Reddy KR. Predicting sustained virological responses in chronic hepatitis C sufferers treated with peginterferon alfa2a (40 KD)/ribavirin. J Hepatol 2005; 43: 425433 [PMID: 15990196 DOI: 10.1016/j.jhep.2005.04.009] Suggestions for Testing, Managing, and Treating Hepatitis C. In: The American Association for the Study of Liver Ailments. The Infectious Ailments Society of America, 2015 European Association for Study of Liver. EASL Clinical Practice Suggestions: management of hepatitis C virus infection. J Hepatol 2014; 60: 392420 [PMID: 24331294 DOI: ten.1016/j. jhep.2013.11.003] Intraobserver and interobserver variations in liver biopsy inter pretation in patients with chronic hepatitis C. The French METAVIR Cooperative Study Group. Hepatology 1994; 20: 1520 [PMID: 8020885] Simmonds P, Alberti A, Alter HJ, Bonino F, Bradley DW, Brechot C, Brouwer JT, Chan SW, Chayama K, Chen DS. A proposed technique for the nomenclature of hepatitis C viral genotypes. Hepatology 1994; 19: 13211324 [PMID: 8175159] Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, Heinzen EL, Qiu P, Bertelsen AH, Muir AJ, Sulkowski M, McHutchison JG, Goldstein DB. Genetic variation in IL28B predicts hepatitis C treatmentinduced viral clearance. Nature 2009; 461: 399401 [PMID: 19684573 DOI: 10.1038/nature08309] Ito K, Higami K, Masaki N, Sugiyama M, Mukaide M, Saito H, Aoki Y, Sato Y, Imamura M, Murata K, Nomura H, Hige S, Adachi H, Hino K, Yatsuhashi H, Orito E, Kani S, Tanaka Y, Mizokami M. The rs8099917 polymorphism, when determined by a appropriate genotyping technique, is actually a much better predictor for response to pegylated alpha interferon/ribavirin therapy in Japanese sufferers than other single nucleotide polymorphisms linked with interleukin28B. J Clin Microbiol 2011; 49: 18531860 [PMID: 21389156 DOI: 10.1128/JCM.0213910] Ogawa E, Furusyo N, Nakamuta M, Kajiwara E, Nomura H, Dohmen K, Takahashi K, Satoh T, Azuma K, Kawano A, Tanabe Y, Kotoh K, Shimoda S, Hayashi J. Clinical milestones for the prediction of severe anemia by chronic hepatitis C patients getting telaprevirbased triple therapy.LIF Protein Storage & Stability J Hepatol 2013; 59: 667674 [PMID: 23707372 DOI: 10.MIF Protein Source 1016/j.PMID:24733396 jhep.2013.05.017] Jacobson IM, Marcellin P, Zeuzem S, Sulkowski MS, Esteban R, Poordad F, Bruno S, Burroughs MH, Pedicone LD, Boparai N, Deng W, DiNubile MJ, Gottesdiener KM, Brass CA, Albrecht JK, Bronowicki JP. Refinement of stopping guidelines in the course of therapy of hepatitis C genotype 1 infection with boceprevir and peginterferon/ ribavirin. Hepatology 2012; 56: 567575 [PMID: 22619063 DOI: 10.1002/hep.25865] Drafting Committee for Hepatitis Management Suggestions, the Japan Society of Hepatology. JSH Suggestions for the Management of Hepatitis C Virus Infection: A 2014 Update forInnovations and breakthroughsThis is definitely the 1st study to report the detailed transition of your viral level through the early stage of DAA therapy for chronic hepatitis C. Importantly, it was found that an undetectable serum viral level at week six, and not at week four or 12, is the most efficient predictor of outcome.ApplicationsChecking the serum viral level at week six will be useful for establishing a response-guided treatment regimen for individuals treated with DAAs, which would assist lower the total duration of remedy.TerminologyVirological response (VR) is defined as undetectable serum hepatitis C virus (HCV) RNA. Sustained virological response (SVR) is VR at 24 wk immediately after the finish of remedy and is regarded a.
